OTCMKTS:SGIOY

Shionogi & Co., Ltd. Stock Forecast, Price & News

$13.23
0.00 (0.00 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.93
Now: $13.23
$13.58
50-Day Range
$12.53
MA: $13.43
$14.10
52-Week Range
$11.49
Now: $13.23
$16.89
Volume1.04 million shs
Average Volume161,145 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. Its primary products Tivicay for HIV treatment; Mulpleta for the treatment of thrombocytopenia; Xofluza, an influenza drug; Symproic for opioid-induced constipation treatment; and Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment. The company also offers antibody detection kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Hsiri Therapeutics Inc.; Nagasaki University; Roche Group to develop and commercialize Xofluza; and Nagasaki University and The Kitasato Institute to develop antimalarial drugs and vaccines. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Shionogi & Co., Ltd. logo

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:SGIOY
CUSIPN/A
CIKN/A
Phone81 6 6202 2161
Employees5,222
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Headlines

China Mobile Considers A-Share Listing After U.S. Removal
March 17, 2021 |  ca.finance.yahoo.com
Shionogi & Co., Ltd. (4507.T)
February 1, 2021 |  finance.yahoo.com
What Wall Street expects from Shionogi's earnings
January 30, 2021 |  markets.businessinsider.com
GSK Jan 2021 35.500 put
January 23, 2021 |  ca.finance.yahoo.com
Shionogi & Co Ltd
January 16, 2021 |  cnbc.com
See More Headlines

MarketRank

Overall MarketRank

0.52 out of 5 stars

Medical Sector

1508th out of 2,019 stocks

Drug Manufacturers - Specialty & Generic Industry

40th out of 61 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$13.23
0.00 (0.00 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SGIOY News and Ratings via Email

Sign-up to receive the latest news and ratings for SGIOY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Frequently Asked Questions

What stocks does MarketBeat like better than Shionogi & Co., Ltd.?

Wall Street analysts have given Shionogi & Co., Ltd. a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Shionogi & Co., Ltd. wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Shionogi & Co., Ltd.?

Shionogi & Co., Ltd. saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 112,600 shares, an increase of 58.1% from the March 15th total of 71,200 shares. Based on an average daily volume of 161,500 shares, the days-to-cover ratio is currently 0.7 days.
View Shionogi & Co., Ltd.'s Short Interest
.

How has Shionogi & Co., Ltd.'s stock been impacted by COVID-19?

Shionogi & Co., Ltd.'s stock was trading at $12.5870 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SGIOY shares have increased by 5.1% and is now trading at $13.23.
View which stocks have been most impacted by COVID-19
.

Who are Shionogi & Co., Ltd.'s key executives?

Shionogi & Co., Ltd.'s management team includes the following people:
  • Dr. Isao Teshirogi, CEO, Pres & Representative Director (Age 62, Pay $1.76M)
  • Ms. Takuko Yamada-Sawada, Exec. VP, Sr. VP of Integrated Disease Care Division & Director (Age 66, Pay $884.45k)
  • Mr. Noriyuki Kishida, Sr. Exec. Officer & Sr. VP of Admin. Division
  • Mr. Yoshimasa Kyokawa, VP of Corp. Communications & Sec. Office
  • Yoshihiro Furuya, VP of Gen. Marketing and Compliance Officer of Corp. GXP Compliance Office
  • Mr. Kohji Hanasaki Ph.D., Sr. Exec. Officer & Sr. VP of Corp. Strategy Division
  • Dr. John A. Keller, Sr. Exec. Officer & Sr. VP of Global Bus. Division (Age 56)
  • Mr. Takeshi Shiota, SVP of Pharmaceutical Research Div, GM of Innovative Drug Discovery Research Labs & Corp Officer
  • Mr. Kazuhiro Hatanaka, Sr. Exec. Officer of Pharmaceutical Commercial Division
  • Akira Kato Ph.D., Corp. Officer & GM of Bus. Devel. Department

Who are some of Shionogi & Co., Ltd.'s key competitors?

What is Shionogi & Co., Ltd.'s stock symbol?

Shionogi & Co., Ltd. trades on the OTCMKTS under the ticker symbol "SGIOY."

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Shionogi & Co., Ltd.'s stock price today?

One share of SGIOY stock can currently be purchased for approximately $13.23.

How many employees does Shionogi & Co., Ltd. have?

Shionogi & Co., Ltd. employs 5,222 workers across the globe.

What is Shionogi & Co., Ltd.'s official website?

The official website for Shionogi & Co., Ltd. is www.shionogi.co.jp.

How can I contact Shionogi & Co., Ltd.?

The company can be reached via phone at 81 6 6202 2161.


This page was last updated on 4/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.